Merit Medical Systems, Inc. cash flow to debt ratio of 33.11% indicates that the company generates enough cash to cover its debts. This level indicates strong financial health.

Merit Medical Systems, Inc.'s free cash flow has increased 16.29% from $182.76M last year to $212.53M, signaling increasing performance

Merit Medical Systems, Inc.'s debt to equity ratio is 0.49, which means that the company's assets are healthy financed, signaling financial stability.

Merit Medical Systems, Inc.'s debt has decreased relative to shareholder equity from 0.58 last year to 0.49 today, signaling strengthened financials

Merit Medical Systems, Inc. has a net debt to EBITDA ratio of 1.35x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Merit Medical Systems, Inc.'s interest coverage ratio of 6.34 indicates that earnings with good margin can cover interest payments on company debt

Merit Medical Systems, Inc.'s profit margin has increased (3.89%) in the last year from 8.87% to 9.22%, signaling increasing performance

Merit Medical Systems, Inc.'s short-term assets of $1.04B exceed its short-term liabilities of $239.76M

Merit Medical Systems, Inc.'s return on assets of 5.08% is higher than the 5.00% threshold, indicating efficient asset utilization

Merit Medical Systems, Inc.'s return on equity of 9.07%, is lower than 15.00%, indicating bad performance

Merit Medical Systems, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Merit Medical Systems, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Merit Medical Systems, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Merit Medical Systems, Inc. has a free cash flow yield of 3.97%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Merit Medical Systems, Inc.'s yearly earnings has increased 6.76% since last year from $120.36M to $128.49M, signaling increasing performance

Merit Medical Systems, Inc.'s yearly revenue has increased 11.75% since last year from $1.36B to $1.52B, signaling increasing performance

ROIC 5.78% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Merit Medical Systems, Inc.'s 3-year revenue CAGR of 9.59% is positive, indicating growing revenue over the past 3 years

Merit Medical Systems, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Merit Medical Systems, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Merit Medical Systems, Inc. is overvalued relative to its fair value price of 56.85 based on Discounted Cash Flow model

Merit Medical Systems, Inc. has an earnings yield of 2.72%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

Merit Medical Systems, Inc. is overvalued relative to its fair value price of 31.55 based on EBITDA multiple model

Merit Medical Systems, Inc. has an EV/EBITDA ratio of 17.49x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Merit Medical Systems, Inc. is overvalued relative to its fair value price of 51.88 based on Earnings Fair Value model

Merit Medical Systems, Inc. had non-positive diluted EPS five years ago; the PEG ratio is not meaningful and the check fails.

Merit Medical Systems, Inc. has a price-to-book ratio of 3.19x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Merit Medical Systems, Inc. has a price-to-sales ratio of 3.39x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue